CD274 and Hodgkins lymphoma: In conclusion, ICI antibodies directed against CTLA-4 or PD-1 and PD-L1 have shown significant activity in several solid cancers, most notably, melanoma and NSCLC and in some hematological neoplasms, in particular classical HL.